Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 41 | 2022 | 1037 | 6.160 |
Why?
|
Mammography | 26 | 2022 | 174 | 4.750 |
Why?
|
Magnetic Resonance Imaging | 17 | 2022 | 105 | 4.540 |
Why?
|
Early Detection of Cancer | 26 | 2022 | 526 | 4.280 |
Why?
|
Textile Industry | 20 | 2015 | 20 | 2.630 |
Why?
|
Breast | 13 | 2022 | 84 | 2.550 |
Why?
|
Occupational Exposure | 22 | 2015 | 67 | 2.410 |
Why?
|
Breast Density | 8 | 2022 | 31 | 1.820 |
Why?
|
Female | 83 | 2022 | 13136 | 1.730 |
Why?
|
Humans | 93 | 2023 | 18430 | 1.610 |
Why?
|
Middle Aged | 58 | 2022 | 8284 | 1.480 |
Why?
|
Mass Screening | 13 | 2022 | 690 | 1.440 |
Why?
|
Lung Neoplasms | 6 | 2021 | 259 | 1.380 |
Why?
|
Neoplasms, Second Primary | 2 | 2020 | 31 | 1.350 |
Why?
|
Ovarian Neoplasms | 4 | 2013 | 50 | 1.320 |
Why?
|
Aged | 51 | 2022 | 6417 | 1.260 |
Why?
|
Occupational Diseases | 14 | 2015 | 42 | 1.230 |
Why?
|
Risk Factors | 30 | 2021 | 3449 | 1.070 |
Why?
|
Colonoscopy | 5 | 2015 | 268 | 0.970 |
Why?
|
Adult | 39 | 2023 | 7910 | 0.930 |
Why?
|
Parity | 3 | 2009 | 74 | 0.910 |
Why?
|
Neoplasms | 8 | 2021 | 457 | 0.870 |
Why?
|
Colorectal Neoplasms | 8 | 2014 | 656 | 0.860 |
Why?
|
Population Surveillance | 6 | 2022 | 271 | 0.830 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 4 | 2011 | 68 | 0.820 |
Why?
|
China | 26 | 2015 | 130 | 0.810 |
Why?
|
Cancer Survivors | 2 | 2022 | 89 | 0.800 |
Why?
|
BRCA1 Protein | 1 | 2020 | 6 | 0.740 |
Why?
|
United States | 23 | 2023 | 4164 | 0.740 |
Why?
|
Dust | 11 | 2015 | 22 | 0.680 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 392 | 0.650 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2022 | 249 | 0.640 |
Why?
|
Advisory Committees | 2 | 2017 | 112 | 0.640 |
Why?
|
Antidepressive Agents | 2 | 2010 | 162 | 0.630 |
Why?
|
Patient Outcome Assessment | 1 | 2018 | 29 | 0.600 |
Why?
|
Cohort Studies | 18 | 2021 | 2672 | 0.590 |
Why?
|
Endometrial Neoplasms | 2 | 2008 | 39 | 0.590 |
Why?
|
Scoliosis | 1 | 2017 | 3 | 0.580 |
Why?
|
Patient Participation | 2 | 2018 | 144 | 0.580 |
Why?
|
Registries | 11 | 2020 | 490 | 0.560 |
Why?
|
Postoperative Complications | 1 | 2017 | 103 | 0.540 |
Why?
|
Risk Assessment | 14 | 2015 | 1143 | 0.540 |
Why?
|
Carcinoma, Basal Cell | 1 | 2016 | 24 | 0.540 |
Why?
|
Melanoma | 1 | 2016 | 37 | 0.530 |
Why?
|
Anesthesia | 1 | 2015 | 4 | 0.530 |
Why?
|
Time Factors | 13 | 2017 | 1136 | 0.530 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 55 | 0.520 |
Why?
|
Skin Neoplasms | 1 | 2016 | 64 | 0.510 |
Why?
|
Incidence | 13 | 2015 | 1314 | 0.510 |
Why?
|
Aged, 80 and over | 13 | 2019 | 2003 | 0.500 |
Why?
|
Mastectomy | 6 | 2022 | 39 | 0.500 |
Why?
|
Age Factors | 9 | 2017 | 965 | 0.490 |
Why?
|
Colonic Neoplasms | 3 | 2013 | 157 | 0.470 |
Why?
|
Healthcare Disparities | 4 | 2018 | 211 | 0.470 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2013 | 5 | 0.460 |
Why?
|
Colonic Polyps | 2 | 2011 | 35 | 0.450 |
Why?
|
Young Adult | 8 | 2021 | 2518 | 0.450 |
Why?
|
Male | 14 | 2018 | 10440 | 0.440 |
Why?
|
Deep Sedation | 1 | 2013 | 3 | 0.440 |
Why?
|
Pelvic Neoplasms | 1 | 2013 | 1 | 0.440 |
Why?
|
Abdominal Neoplasms | 1 | 2013 | 2 | 0.440 |
Why?
|
Colonography, Computed Tomographic | 1 | 2013 | 10 | 0.440 |
Why?
|
Odds Ratio | 8 | 2015 | 701 | 0.430 |
Why?
|
Case-Control Studies | 10 | 2023 | 1173 | 0.420 |
Why?
|
Logistic Models | 9 | 2017 | 962 | 0.400 |
Why?
|
Contraceptives, Oral | 2 | 2008 | 26 | 0.390 |
Why?
|
Rectal Neoplasms | 2 | 2009 | 67 | 0.390 |
Why?
|
Survivors | 2 | 2022 | 158 | 0.380 |
Why?
|
Decision Making | 4 | 2022 | 204 | 0.380 |
Why?
|
Stomach Neoplasms | 2 | 2015 | 42 | 0.370 |
Why?
|
Patient Acceptance of Health Care | 2 | 2014 | 407 | 0.370 |
Why?
|
Health Care Costs | 1 | 2013 | 251 | 0.370 |
Why?
|
Esophageal Neoplasms | 2 | 2015 | 116 | 0.360 |
Why?
|
Medicare | 6 | 2018 | 214 | 0.360 |
Why?
|
Body Size | 1 | 2010 | 31 | 0.360 |
Why?
|
Endotoxins | 9 | 2010 | 9 | 0.350 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 78 | 0.350 |
Why?
|
Tomography, X-Ray Computed | 3 | 2021 | 208 | 0.350 |
Why?
|
Proportional Hazards Models | 11 | 2015 | 743 | 0.350 |
Why?
|
Gravidity | 1 | 2009 | 8 | 0.340 |
Why?
|
Influenza Vaccines | 2 | 2023 | 290 | 0.330 |
Why?
|
Influenza, Human | 2 | 2023 | 282 | 0.330 |
Why?
|
Preoperative Care | 3 | 2018 | 19 | 0.330 |
Why?
|
Adenoma | 1 | 2010 | 100 | 0.330 |
Why?
|
Washington | 4 | 2021 | 388 | 0.320 |
Why?
|
Silk | 1 | 2008 | 1 | 0.320 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 321 | 0.310 |
Why?
|
Practice Guidelines as Topic | 4 | 2020 | 333 | 0.310 |
Why?
|
Hormone Replacement Therapy | 1 | 2008 | 28 | 0.310 |
Why?
|
Pandemics | 4 | 2023 | 292 | 0.280 |
Why?
|
Multivariate Analysis | 4 | 2017 | 598 | 0.280 |
Why?
|
Patient Education as Topic | 2 | 2020 | 214 | 0.280 |
Why?
|
Evidence-Based Medicine | 3 | 2017 | 195 | 0.280 |
Why?
|
Air Pollutants, Occupational | 4 | 2008 | 16 | 0.270 |
Why?
|
Menarche | 1 | 2006 | 30 | 0.270 |
Why?
|
Influenza A Virus, H1N1 Subtype | 2 | 2023 | 56 | 0.270 |
Why?
|
Influenza A Virus, H3N2 Subtype | 2 | 2023 | 14 | 0.260 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 414 | 0.260 |
Why?
|
Wisconsin | 3 | 2010 | 10 | 0.260 |
Why?
|
Biopsy | 4 | 2021 | 75 | 0.250 |
Why?
|
Prospective Studies | 7 | 2017 | 1314 | 0.250 |
Why?
|
Patient Selection | 2 | 2017 | 198 | 0.250 |
Why?
|
Cardiovascular Diseases | 1 | 2010 | 630 | 0.240 |
Why?
|
Adolescent | 7 | 2022 | 3798 | 0.240 |
Why?
|
Textiles | 3 | 2010 | 3 | 0.230 |
Why?
|
Postmenopause | 3 | 2022 | 267 | 0.230 |
Why?
|
Risk | 3 | 2017 | 552 | 0.230 |
Why?
|
Guideline Adherence | 2 | 2016 | 162 | 0.230 |
Why?
|
Cross-Sectional Studies | 4 | 2022 | 1360 | 0.220 |
Why?
|
Socioeconomic Factors | 4 | 2017 | 673 | 0.210 |
Why?
|
Emotions | 1 | 2022 | 35 | 0.210 |
Why?
|
Influenza A virus | 1 | 2022 | 14 | 0.200 |
Why?
|
Retrospective Studies | 4 | 2017 | 2550 | 0.200 |
Why?
|
Surveys and Questionnaires | 5 | 2014 | 1389 | 0.200 |
Why?
|
Age Distribution | 2 | 2020 | 261 | 0.190 |
Why?
|
Triage | 1 | 2021 | 17 | 0.190 |
Why?
|
Health Care Rationing | 1 | 2021 | 14 | 0.190 |
Why?
|
Medical Informatics | 1 | 2021 | 45 | 0.190 |
Why?
|
Physical Examination | 2 | 2021 | 21 | 0.190 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 252 | 0.190 |
Why?
|
Pregnancy | 5 | 2010 | 1516 | 0.190 |
Why?
|
Reproducibility of Results | 2 | 2019 | 399 | 0.180 |
Why?
|
Pamphlets | 1 | 2020 | 8 | 0.180 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2012 | 412 | 0.180 |
Why?
|
Mutation | 1 | 2020 | 132 | 0.180 |
Why?
|
Awareness | 1 | 2020 | 18 | 0.180 |
Why?
|
Perception | 1 | 2019 | 59 | 0.170 |
Why?
|
Longitudinal Studies | 2 | 2019 | 724 | 0.170 |
Why?
|
False Positive Reactions | 3 | 2013 | 26 | 0.160 |
Why?
|
Abortion, Spontaneous | 2 | 2010 | 52 | 0.160 |
Why?
|
Anticarcinogenic Agents | 2 | 2010 | 14 | 0.160 |
Why?
|
Communication | 1 | 2020 | 202 | 0.150 |
Why?
|
Research Support as Topic | 1 | 2018 | 23 | 0.150 |
Why?
|
Health Services Accessibility | 2 | 2018 | 320 | 0.150 |
Why?
|
Obesity | 2 | 2017 | 855 | 0.150 |
Why?
|
Trust | 1 | 2018 | 31 | 0.150 |
Why?
|
Smoking | 5 | 2017 | 494 | 0.150 |
Why?
|
Language | 1 | 2018 | 52 | 0.150 |
Why?
|
Quality Improvement | 2 | 2017 | 207 | 0.150 |
Why?
|
Databases, Factual | 2 | 2016 | 327 | 0.150 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2018 | 57 | 0.150 |
Why?
|
Spine | 1 | 2017 | 7 | 0.150 |
Why?
|
Spinal Fusion | 1 | 2017 | 5 | 0.150 |
Why?
|
Gonadal Steroid Hormones | 2 | 2022 | 33 | 0.140 |
Why?
|
Health Personnel | 1 | 2018 | 126 | 0.140 |
Why?
|
Clinical Protocols | 1 | 2017 | 45 | 0.140 |
Why?
|
Telephone | 2 | 2017 | 179 | 0.140 |
Why?
|
Cotton Fiber | 4 | 2010 | 4 | 0.140 |
Why?
|
Medical Oncology | 2 | 2014 | 32 | 0.140 |
Why?
|
Dermatology | 1 | 2016 | 6 | 0.140 |
Why?
|
Tumor Burden | 1 | 2016 | 20 | 0.140 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 65 | 0.140 |
Why?
|
Safety-net Providers | 1 | 2017 | 63 | 0.140 |
Why?
|
International Cooperation | 2 | 2013 | 17 | 0.140 |
Why?
|
Decision Support Techniques | 1 | 2017 | 95 | 0.130 |
Why?
|
Delivery of Health Care | 1 | 2020 | 444 | 0.130 |
Why?
|
Cost-Benefit Analysis | 2 | 2016 | 270 | 0.130 |
Why?
|
SEER Program | 4 | 2018 | 101 | 0.130 |
Why?
|
Ethnic Groups | 2 | 2017 | 501 | 0.130 |
Why?
|
Social Class | 1 | 2015 | 125 | 0.130 |
Why?
|
Work Schedule Tolerance | 1 | 2014 | 7 | 0.120 |
Why?
|
Comorbidity | 2 | 2017 | 619 | 0.120 |
Why?
|
Primary Health Care | 3 | 2016 | 848 | 0.120 |
Why?
|
Preventive Health Services | 1 | 2016 | 166 | 0.120 |
Why?
|
Hyperplasia | 2 | 2011 | 6 | 0.110 |
Why?
|
Patient Compliance | 1 | 2016 | 318 | 0.110 |
Why?
|
Magnetic Fields | 1 | 2013 | 6 | 0.110 |
Why?
|
Reminder Systems | 1 | 2014 | 94 | 0.110 |
Why?
|
Promoter Regions, Genetic | 1 | 2012 | 15 | 0.110 |
Why?
|
Estrogen Receptor beta | 1 | 2012 | 12 | 0.110 |
Why?
|
Influenza B virus | 2 | 2023 | 8 | 0.110 |
Why?
|
Estrogen Replacement Therapy | 1 | 2013 | 104 | 0.110 |
Why?
|
Radiology | 3 | 2021 | 9 | 0.110 |
Why?
|
Biomedical Research | 1 | 2013 | 93 | 0.100 |
Why?
|
Body Mass Index | 3 | 2017 | 974 | 0.100 |
Why?
|
Survival Rate | 1 | 2013 | 269 | 0.100 |
Why?
|
Seasons | 2 | 2023 | 105 | 0.100 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 46 | 0.100 |
Why?
|
Silicon Dioxide | 2 | 2010 | 3 | 0.100 |
Why?
|
Self Report | 1 | 2013 | 256 | 0.100 |
Why?
|
Epoxide Hydrolases | 1 | 2011 | 2 | 0.100 |
Why?
|
Prognosis | 1 | 2013 | 624 | 0.090 |
Why?
|
Neoplasm Staging | 3 | 2018 | 337 | 0.090 |
Why?
|
Outcome Assessment (Health Care) | 1 | 2012 | 254 | 0.090 |
Why?
|
Meat | 1 | 2011 | 27 | 0.090 |
Why?
|
Child | 3 | 2023 | 2571 | 0.090 |
Why?
|
Reproductive History | 2 | 2013 | 18 | 0.090 |
Why?
|
Follow-Up Studies | 2 | 2011 | 1269 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 197 | 0.090 |
Why?
|
Human Growth Hormone | 1 | 2010 | 2 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2010 | 17 | 0.090 |
Why?
|
Colon | 1 | 2010 | 21 | 0.090 |
Why?
|
Physical Exertion | 1 | 2010 | 22 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2012 | 228 | 0.090 |
Why?
|
Cause of Death | 1 | 2010 | 185 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2009 | 100 | 0.080 |
Why?
|
Insurance, Health | 1 | 2011 | 217 | 0.080 |
Why?
|
Infant | 2 | 2023 | 1245 | 0.080 |
Why?
|
Regression Analysis | 1 | 2009 | 319 | 0.080 |
Why?
|
Ovulation | 1 | 2008 | 5 | 0.080 |
Why?
|
Gram-Negative Bacteria | 1 | 2008 | 4 | 0.080 |
Why?
|
Motor Activity | 1 | 2010 | 215 | 0.080 |
Why?
|
Residence Characteristics | 3 | 2017 | 256 | 0.080 |
Why?
|
Child, Preschool | 2 | 2023 | 1478 | 0.080 |
Why?
|
Inflammation | 1 | 2008 | 63 | 0.080 |
Why?
|
Massachusetts | 1 | 2008 | 99 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2008 | 131 | 0.070 |
Why?
|
Vaccination | 2 | 2023 | 674 | 0.070 |
Why?
|
Epidemiological Monitoring | 4 | 2010 | 27 | 0.070 |
Why?
|
Inhalation Exposure | 1 | 2007 | 5 | 0.070 |
Why?
|
Environmental Monitoring | 4 | 2010 | 26 | 0.070 |
Why?
|
Contraceptive Agents, Female | 1 | 2007 | 12 | 0.070 |
Why?
|
Survival Analysis | 1 | 2008 | 226 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 182 | 0.070 |
Why?
|
Treatment Outcome | 1 | 2010 | 1296 | 0.070 |
Why?
|
Abortion, Induced | 1 | 2006 | 17 | 0.070 |
Why?
|
Biliary Tract Neoplasms | 1 | 2006 | 15 | 0.070 |
Why?
|
Pilot Projects | 2 | 2020 | 237 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 365 | 0.070 |
Why?
|
Brain Neoplasms | 1 | 2006 | 15 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2008 | 342 | 0.070 |
Why?
|
Menopause | 1 | 2006 | 72 | 0.070 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2006 | 1 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2005 | 12 | 0.070 |
Why?
|
Patient Satisfaction | 2 | 2020 | 232 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2005 | 42 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2006 | 69 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 567 | 0.060 |
Why?
|
Hispanic Americans | 2 | 2017 | 428 | 0.060 |
Why?
|
European Continental Ancestry Group | 2 | 2017 | 554 | 0.060 |
Why?
|
Workplace | 1 | 2003 | 36 | 0.060 |
Why?
|
Epidemiologic Methods | 3 | 2010 | 87 | 0.060 |
Why?
|
Research | 1 | 2003 | 73 | 0.050 |
Why?
|
African Americans | 2 | 2017 | 490 | 0.050 |
Why?
|
Presenteeism | 1 | 2023 | 2 | 0.050 |
Why?
|
Vaccines, Inactivated | 1 | 2023 | 70 | 0.050 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 58 | 0.050 |
Why?
|
Likelihood Functions | 2 | 2014 | 48 | 0.050 |
Why?
|
Tamoxifen | 1 | 2022 | 60 | 0.050 |
Why?
|
Testosterone | 1 | 2022 | 22 | 0.050 |
Why?
|
Estradiol | 1 | 2022 | 24 | 0.050 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2022 | 23 | 0.050 |
Why?
|
Medical History Taking | 1 | 2021 | 37 | 0.050 |
Why?
|
Focus Groups | 1 | 2021 | 154 | 0.050 |
Why?
|
Reference Standards | 1 | 2020 | 17 | 0.040 |
Why?
|
Boston | 1 | 2020 | 37 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2010 | 253 | 0.040 |
Why?
|
Health Facilities | 1 | 2018 | 18 | 0.040 |
Why?
|
Mastectomy, Segmental | 1 | 2017 | 23 | 0.040 |
Why?
|
Chemoprevention | 1 | 2017 | 12 | 0.040 |
Why?
|
Social Stigma | 1 | 2017 | 19 | 0.040 |
Why?
|
Benchmarking | 1 | 2017 | 45 | 0.040 |
Why?
|
Self Efficacy | 1 | 2017 | 71 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2017 | 327 | 0.030 |
Why?
|
Insurance Claim Review | 1 | 2016 | 70 | 0.030 |
Why?
|
Research Design | 2 | 2010 | 402 | 0.030 |
Why?
|
Health Services | 1 | 2017 | 117 | 0.030 |
Why?
|
Qualitative Research | 1 | 2017 | 272 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 29 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2017 | 147 | 0.030 |
Why?
|
Educational Status | 1 | 2015 | 205 | 0.030 |
Why?
|
Counseling | 1 | 2017 | 197 | 0.030 |
Why?
|
Internet | 1 | 2017 | 243 | 0.030 |
Why?
|
Continental Population Groups | 1 | 2017 | 315 | 0.030 |
Why?
|
Sex Factors | 1 | 2017 | 661 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2016 | 136 | 0.030 |
Why?
|
Sigmoidoscopy | 1 | 2014 | 67 | 0.030 |
Why?
|
Women's Health | 1 | 2014 | 207 | 0.030 |
Why?
|
Occult Blood | 1 | 2014 | 167 | 0.030 |
Why?
|
Health Care Reform | 1 | 2012 | 33 | 0.030 |
Why?
|
Community Health Services | 1 | 2013 | 86 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 77 | 0.030 |
Why?
|
Prevalence | 1 | 2014 | 911 | 0.020 |
Why?
|
Disease Progression | 1 | 2012 | 271 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 2014 | 350 | 0.020 |
Why?
|
Benzo(a)pyrene | 1 | 2011 | 1 | 0.020 |
Why?
|
Cooking | 1 | 2011 | 17 | 0.020 |
Why?
|
Hot Temperature | 1 | 2011 | 8 | 0.020 |
Why?
|
Formaldehyde | 1 | 2010 | 5 | 0.020 |
Why?
|
Health Behavior | 1 | 2013 | 374 | 0.020 |
Why?
|
Genotype | 1 | 2011 | 253 | 0.020 |
Why?
|
Developing Countries | 1 | 2010 | 16 | 0.020 |
Why?
|
Animals | 1 | 2011 | 261 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2010 | 159 | 0.020 |
Why?
|
Quality of Life | 1 | 2012 | 529 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 2010 | 193 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2007 | 6 | 0.020 |
Why?
|
Injections | 1 | 2007 | 5 | 0.020 |
Why?
|
Reproduction | 1 | 2007 | 12 | 0.020 |
Why?
|
Confounding Factors (Epidemiology) | 1 | 2007 | 99 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2007 | 131 | 0.020 |
Why?
|
Hazardous Substances | 1 | 2005 | 3 | 0.020 |
Why?
|
Coloring Agents | 1 | 2005 | 4 | 0.020 |
Why?
|
Metals | 1 | 2005 | 6 | 0.020 |
Why?
|
Marital Status | 1 | 2005 | 22 | 0.020 |
Why?
|
Life Style | 1 | 2007 | 342 | 0.020 |
Why?
|
Ethics, Research | 1 | 2003 | 1 | 0.010 |
Why?
|
Forms and Records Control | 1 | 2003 | 7 | 0.010 |
Why?
|
Breast Self-Examination | 1 | 2003 | 6 | 0.010 |
Why?
|
Informed Consent | 1 | 2003 | 20 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2005 | 375 | 0.010 |
Why?
|